HealthcareServices

Neurotrophic Keratitis Treatment Market Size and Demand Forecast 2026–2030

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neurotrophic keratitis treatment market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Neurotrophic Keratitis Treatment Market show for the 2026–2030 period?_x000D_

The neurotrophic keratitis treatment market has seen significant expansion in recent years. It is anticipated to increase from $1.47 billion in 2025 to $1.99 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 36.1%. This historical market growth is attributable to factors such as the growing prevalence of diabetes-related corneal disorders, a rise in herpes simplex eye infections, the development of ophthalmology specialty clinics, enhanced understanding of neurotrophic keratitis among medical professionals, and the broadening of hospital-based eye care provisions._x000D_

_x000D_

The neurotrophic keratitis treatment market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $6.78 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 35.8%. The anticipated growth during this period is fueled by several factors, including breakthroughs in regenerative ophthalmic treatments, a rise in the approval of rhNGF-based medications, an expanding elderly demographic facing nerve degeneration risks, increased funding for research into rare eye conditions, and broader availability of sophisticated eye care services in developing regions. Key trends foreseen for the forecast horizon encompass a greater embrace of recombinant human nerve growth factor treatments, a developing inclination towards less invasive corneal repair methods, a heightened emphasis on prompt diagnosis and intervention, the proliferation of home-based ophthalmic care options, and enhancements in techniques for preserving amniotic membranes._x000D_

_x000D_

#Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=12968&type=smp_x000D_

_x000D_

What Drivers Are Shaping The Development Of The Neurotrophic Keratitis Treatment Market?_x000D_

The increasing occurrence of eye conditions is anticipated to drive the expansion of the neurotrophic keratitis treatment market moving ahead. Eye ailments encompass numerous conditions impacting the eyes’ structure and operation, potentially resulting in compromised sight or complete vision loss. The rise in eye disease frequency stems from elements like an aging population, shifts in lifestyle, and the rising rates of persistent conditions such as diabetes. Treatment for neurotrophic keratitis aids ocular health through enhancing corneal sensation, fostering recovery, averting infections, and easing discomfort. For example, data from August 2023, provided by the World Health Organization (WHO), a United Nations agency based in Switzerland, revealed that an estimated 2.2 billion individuals globally experience near or distance vision impairment. Of these, 1 billion cases could have been prevented or remain unaddressed. Refractive errors and cataracts continue to be the primary worldwide reasons for vision loss, yet only 36% of those with refractive-error-related distance impairment and merely 17% of those with cataract-related impairment have received the necessary care. Consequently, the expanding occurrence of eye conditions is fueling the growth within the neurotrophic keratitis treatment market._x000D_

_x000D_

What Segment Types Are Examined In The Neurotrophic Keratitis Treatment Market?_x000D_

The neurotrophic keratitis treatment market covered in this report is segmented –_x000D_

_x000D_

1) By Treatment: Topical Antibiotics, Recombinant Human Nerve Growth Factor (rhNGF), Amniotic Membrane Transplantation, Keratoplasty, Other Treatments_x000D_

2) By Route Of Administration: Oral, Topical, Other Routes Of Administrations_x000D_

3) By Application: Stage I, Stage II, Stage III_x000D_

4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Topical Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics_x000D_

2) By Recombinant Human Nerve Growth Factor (rhNGF): Cenegermin Ophthalmic Solution_x000D_

3) By Amniotic Membrane Transplantation: Cryopreserved Amniotic Membrane, Dehydrated Amniotic Membrane_x000D_

4) By Keratoplasty: Penetrating Keratoplasty, Lamellar Keratoplasty_x000D_

5) By Other Treatments: Tarsorrhaphy, Therapeutic Contact Lenses_x000D_

_x000D_

How Are Emerging Trends Affecting The Progression Of The Neurotrophic Keratitis Treatment Market?_x000D_

Leading firms within the neurotrophic keratitis market are prioritizing the creation of sophisticated gene-therapy options, including redosable eye-drop treatments, with the goals of enhancing corneal recovery, ensuring continuous nerve growth factor (NGF) expression, and alleviating the treatment load for patients. This type of gene therapy, administered as redosable eye drops, represents a treatment method that introduces genes for NGF directly into the cornea, thereby facilitating extended NGF synthesis and promoting nerve regrowth across a duration. As an illustration, Krystal Biotech, a US-based biotechnology enterprise, disclosed in July 2025 that the initial patient had received a dose in its Phase 1/2 EMERALD 1 study, which is a randomized, double-masked, placebo-controlled investigation enrolling up to 27 adults suffering from stage 2 or 3 neurotrophic keratitis. Intended for administration twice weekly over eight weeks, KB801 seeks to safely advance corneal repair and substantially lessen the treatment obligation when contrasted with current six-times-a-day recombinant NGF eye drops._x000D_

_x000D_

Who Are The Core Companies Influencing Trends In The Neurotrophic Keratitis Treatment Market?_x000D_

Major companies operating in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Johnson & Johnson, Allergan Inc, Alcon Inc, Bausch Health Companies Inc, Bausch & Lomb Inc, CooperVision Inc, Santen Pharmaceutical Co Ltd, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc, Laboratoires Thea SAS, ReGenTree LLC, Contacare Ophthalmic Private Limited, Neuroptika Inc, Surgitech Innovation Private Limited, Aerie Pharmaceuticals Inc, RegeneRx Biopharmaceuticals Inc, Noveome Biotherapeutics Inc, Oyster Point Pharma, Claris Biotherapeutics, Recordati Rare Diseases, Mitotech SA, Kala Pharmaceuticals, Oxurion NV_x000D_

_x000D_

#Access The Complete Report For Deeper Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report_x000D_

_x000D_

Which Region Is Expected To Experience The Fastest Growth In The Neurotrophic Keratitis Treatment Market?_x000D_

North America was the largest region in the neurotrophic keratitis treatment market in 2025. The regions covered in the neurotrophic keratitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request Your Customized Neurotrophic Keratitis Treatment Market Research Report for Competitive Advantage:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=12968&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Neurotrophic Keratitis Treatment Market 2026, By The Business Research Company#_x000D_

_x000D_

Neuralgia Treatment Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report_x000D_

_x000D_

Peripheral Neuropathy Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report_x000D_

_x000D_